Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Advancing Patient Care with Antibody-Drug Conjugate Therapies in HER2-Negative and HER2-Low Metastatic Breast Cancer : Episode 15
Opinion
Video
Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health
Panelists discuss how optimizing antibody-drug conjugate (ADC) therapy in patients with metastatic breast cancer (mBC) requires interdisciplinary care, including oncologists, pharmacists, and nurses. Adherence barriers such as cost, access, and insurance are addressed via financial and social support.
Video Player is loading.
Video content above has been prompted by the following:
- What interdisciplinary approaches to care can help optimize ADC therapy outcomes in patients with mBC?
- Do patients receiving ADC therapy at your practice experience adherence barriers due to social determinants of health, treatment costs, accessibility, or insurance coverage?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Videos
Additional Considerations for LDL-C–Lowering Therapies
Monitoring Patients for Adverse Events and Optimizing Access to Therapies
Personalized Care: How Do NSCLC Treatment Modifications and Patient-Specific Factors Impact Health Outcomes?
Tailoring Therapy: Weighing Evidence, Organ Involvement, and Route of Administration
Steroid-Refractory cGVHD: A Look at FDA-Approved Options
Streamlining the Route of Administration of Monoclonal Antibody Therapies for Better Patient Outcomes in the NSCLC Population
Patient Education for LDL-C–Lowering Therapies
Identifying Nonadherence in Patients With Hyperlipidemia
Navigating the Path to Second-Line Therapy
Infusion Hesitancy and the Impact of Route of Administration of NSCLC Treatment Options in Patients’ Quality of Life
Related Content
